The Hematology Research Training Program at the University of Washington is designed to provide intensive post-doctoral research training in investigative hematology. The program emphasizes cell and molecular biology, with particular strengths in: stem cells and hematopoiesis, cell and gene therapy, platelets and hemostasis, vascular biology, hematologic malignancies, cancer biology, and hematopoietic cell transplantation. Program faculty includes established investigators with strong independent research programs from both basic science and clinical departments at the University of Washington, Fred Hutchinson Cancer Research Center, and nearby affiliated institutions. The goal of the Training Program is to develop the research, presentation, and fund-raising skills that trainees will need to establish independent research careers, and to train future leaders in the field of research hematology. Trainees have MD, MD/PhD or PhD degrees. Many have completed clinical training in hematology, but others are basic researchers wishing to work in the field. Trainees are chosen through an application process and interactions with program faculty. They obtain laboratory experience by working with a mentor, and are assisted in laboratory techniques, publishing papers, presentation skills, and acquiring independent grant support. Trainees typically receive 2 years of funding from the Program, but often continue their training longer under separate funding mechanisms. Training progress is monitored by the faculty mentor, a separate faculty advisor, the Program Directors, and the Division of Hematology faculty through regular research presentations and meetings with each trainee. The main strengths of the Program include: diverse research opportunities, a qualified senior faculty, and a long track record, spanning over four decades of graduates obtaining junior faculty positions and becoming independent and distinguished investigators.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-J (O2))
Program Officer
Chang, Henry
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Buckley, Sarah A; Jimenez-Sahagun, Diana; Othus, Megan et al. (2018) Quality of life from the perspective of the patient with acute myeloid leukemia. Cancer 124:145-152
Baker, Kathryn T; Salk, Jesse J; Brentnall, Teresa A et al. (2018) Precancer in ulcerative colitis: the role of the field effect and its clinical implications. Carcinogenesis 39:11-20
Klein, Jason C; Keith, Aidan; Agarwal, Vikram et al. (2018) Functional characterization of enhancer evolution in the primate lineage. Genome Biol 19:99
Halpern, Anna B; Othus, Megan; Huebner, Emily M et al. (2018) Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms. Leukemia :
Hart, Matthew R; Anderson, Donovan J; Porter, Christopher C et al. (2018) Activating PAX gene family paralogs to complement PAX5 leukemia driver mutations. PLoS Genet 14:e1007642
Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334
Samuelson Bannow, B T; Konkle, B A (2018) Laboratory biomarkers for venous thromboembolism risk in patients with hematologic malignancies: A review. Thromb Res 163:138-145
Wang, Tzu-Fei; Li, Ang; Garcia, David (2018) Managing thrombosis in cancer patients. Res Pract Thromb Haemost 2:429-438
Appelbaum, Jacob; Wells, David; Hiatt, Joseph B et al. (2018) Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. J Immunother Cancer 6:82
Correnti, Colin E; Laszlo, George S; de van der Schueren, Willem J et al. (2018) Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation. Leukemia 32:1239-1243

Showing the most recent 10 out of 105 publications